中文摘要：

目的探讨他克莫司（FK506）与环孢菌素A（CsA）对肝移植受者CD8^＋CD28^-调节性T细胞（Treg）及细胞因子IL-10的调节效应。方法采用荧光标记单克隆抗体结合流式细胞技术分析接受FK506或CsA治疗的肝移植受者外周血CD8^＋T细胞及共刺激分子CD28的表达情况，采用流式细胞小球微阵列术（CBA）分析血浆中IL-10浓度。以健康志愿者和患终末期肝脏疾病拟进行肝移植者作为对照。结果疾病对照组CD8^＋T细胞和CD8^＋CD28^-T细胞／CD8^＋CD28^＋T细胞比值（Ratio值）显著低于健康对照组（P〈0．05）。FK506治疗组CD8^＋T细胞表达显著回升（P〈0．05），且增加的CD8^＋T细胞主要为CD8^＋CD28^-Treg（P〈0．05）。CsA治疗组CD8^＋T细胞和CD8^＋CD28^-Treg未出现明显回升（P〉0．05）。且FK506治疗组CD8^＋CD28^-Treg表达显著高于CsA治疗组（P〈0．05）。两治疗组血浆IL-10水平均显著高于健康对照组和疾病对照组（P〈0．05），但组间差别无显著性（P〉0．05）。结论FK506可促进肝移植受者外周血CD8^＋CD28^-Treg表达并同时促进IL-10的产生从而加强T细胞的免疫耐受，而CsA虽不能有效促进CD8^＋CD28^-Treg的表达但却能促进IL-10的产生。

英文摘要：

Objective To explore the regulatory effects of Tacrolimus （FK506） and cyclosporine A （CsA） on peripheral CD8^＋ CD28^-regulatory T lymphocyte （Treg） and cytokine IL-10. Methods Fluorescein-labelled monoclonal antibodies and flow cytometry were used to determine the expressions of CD8^＋ T lymphocytes and co-stimulator CD28 on peripheral T cells of allo-liver recipients treated with FK506 or CsA. The plasma concentration of IL-10 was determined with Cytometric Beads Array （CBA） kit. Health volunteers and patients suffered severe hepatic diseases and intended to receive liver transplantation were used as controls. Results In those of disease-control group, CD8^＋ T cells and ratio of CD8^＋ CD28^- T cell/CD8^＋ CD28^＋ T cell were much lower than that in health-control group （ P 〈 0.05）. In the FK506-treated group, CD8^＋ T cells increased significantly （ P 〈 0.05） ,and the increased CD8^＋ T cells were mainly CD8^＋ CD28^- Treg （ P 〈 0.05）. In CsA treatment group, the expressions of CD8^＋ T cells and CD8^＋ CD28^- Treg didn＇ t increase significantly （ P 〉 0. 05）. And the expression of CD8^＋ CD28^- Treg in FK506-treated group was much higher than that in CsA-treated group （ P 〈 0.05）. The concentration of IL-10 in both treatment groups were obviously higher than that of the control groups （ P 〈 0. 05）, but there was no significant difference between two treatment groups （P 〉 0. 05）. Conclusion FK506 can promote the expressions of peripheral CD8^＋ CD28^- Treg cells and plasmatic IL-10 in allo-liver recipients, so that enhances T cell tolerance, while CsA is unable to promote the expression of CD8^＋ CD28^- Treg cells but can up-regulate the expression of IL-10.